Abstract | OBJECTIVES: Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to receive the best clinical benefit. Data from the MM-002, MM-003, and MM-010 trials were pooled to further characterize the safety profile of pomalidomide plus low-dose dexamethasone and AE management. METHODS: RESULTS: CONCLUSIONS:
Pomalidomide plus low-dose dexamethasone showed an acceptable safety profile, and AEs were well managed according to study protocols and established guidelines.
|
Authors | Philippe Moreau, Meletios A Dimopoulos, Paul G Richardson, David S Siegel, Michele Cavo, Paolo Corradini, Katja Weisel, Michel Delforge, Peter O'Gorman, Kevin Song, Christine Chen, Nizar Bahlis, Albert Oriol, Markus Hansson, Martin Kaiser, Pekka Anttila, Reinier Raymakers, Cristina Joao, Gordon Cook, Lars Sternas, Tsvetan Biyukov, Ana Slaughter, Kevin Hong, Jennifer Herring, Xin Yu, Mohamed Zaki, Jesus San-Miguel |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 99
Issue 3
Pg. 199-206
(Sep 2017)
ISSN: 1600-0609 [Electronic] England |
PMID | 28504846
(Publication Type: Journal Article)
|
Copyright | © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Thalidomide
- Dexamethasone
- pomalidomide
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Clinical Trials as Topic
- Combined Modality Therapy
- Dexamethasone
(administration & dosage)
- Disease Management
- Drug Resistance, Neoplasm
- Drug-Related Side Effects and Adverse Reactions
(diagnosis, therapy)
- Humans
- Middle Aged
- Multicenter Studies as Topic
- Multiple Myeloma
(drug therapy, pathology)
- Neoplasm Recurrence, Local
- Thalidomide
(administration & dosage, analogs & derivatives)
- Time Factors
|